Diagnóstico y tratamiento de cáncer de próstata.pptx

DIAGNOSTICO Y TRATAMIENTO DE CANCER DE PROSTATA

1. Diagnóstico y tratamiento de cáncer de próstata R1MI Alejandra Giselle Estrada Jiménez

2. El cáncer de próstata es el cáncer más comúnmente diagnosticado, contribuye al 29% de todos los nuevos diagnósticos en hombres y es la segunda causa principal de muerte por cáncer en los hombres estadounidenses. En 2024, se estima que 299.010 estadounidenses serán diagnosticados con cáncer de próstata y 35.250 morirán a causa de esta enfermedad. Version 3.2024, 03/08/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

3. EVALUACIÓN DE DETECCIÓN TEMPRANA Antecedentes y exámenes físicos: Antecedentes familiares de cáncer Antecedentes familiares o personales de mutaciones de la línea germinal de alto riesgo Antecedentes de enfermedad de próstata y detección temprana de cáncer. incluido el antígeno prostático específico (PSA) previo y/ o isoformas , exámenes y biopsias Identificados como negros/afroamericanos Medicamentos Exposición ambiental BRCA2 (5%), ATM (2%), CHEK2 (2%), BRCA1 (1%), RAD51D (0.4%), PALB2 (0.4%), ATR (0.3%), NBN, PMS2, GEN1, MSH2, MSH6, RAD51C, MRE11A, BRIP1, FAM175A Version 3.2024, 03/08/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

4. Version 3.2024, 03/08/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN .

5. Version 3.2024, 03/08/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

6. Biomarcadores % fPSA : <20% densidad del PSA: >0.15 ng / mL /g PCA3 Índice de Salud de la Próstata (PHI) es una combinación de las pruebas tPSA , fPSA y proPSA : >24 4Kscore es otra prueba combinada que mide fPSA , tPSA , calicreína humana 2: si en un paciente da un riesgo de 7% significa que de cada 100 personas en la misma situación solo 7 van a tener un cáncer de próstata Version 3.2024, 03/08/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

7. Version 3.2024, 03/08/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

8. Version 3.2024, 03/08/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

9. Version 3.2024, 03/08/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

10. PSA cada 6 meses DRE cada 12 meses a menos que esté clínicamente indicado. Repetir la biopsia cada 12 meses Someterse a biopsias de próstata cada 2 a 5 años Repetir la mpMRI cada 12 meses. Los pacientes deben pasar a observación cuando la esperanza de vida sea <10 años. No se debe realizar una evaluación de estadificación metastásica (PET con PSMA, gammagrafía ósea, tomografía computarizada o resonancia magnética de cuerpo entero) Version 3.2024, 03/08/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

11. Version 3.2024, 03/08/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

12. Version 3.2024, 03/08/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

13. Version 3.2024, 03/08/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

14. Version 3.2024, 03/08/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

15. Version 3.2024, 03/08/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

16. Version 3.2024, 03/08/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

17. Version 3.2024, 03/08/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

18. Version 3.2024, 03/08/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

19. Version 3.2024, 03/08/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

20. Version 3.2024, 03/08/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

21. Version 3.2024, 03/08/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

22. Version 3.2024, 03/08/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.